Surveillance of influenza B severe hospitalized cases during 10 seasons in Catalonia: Does the lineage make a difference?
Influenza B virus
lineage
surveillance
vaccine
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
07
05
2022
received:
07
03
2022
accepted:
17
05
2022
pubmed:
21
5
2022
medline:
16
7
2022
entrez:
20
5
2022
Statut:
ppublish
Résumé
Influenza B viruses circulate in two lineages (B/Victoria and B/Yamagata). Although classically affecting children, recently it has shown a high rate of infection and increased hospitalization in the elderly. To describe and analyze the clinical and epidemiological characteristics of severe hospitalized laboratory-confirmed influenza B virus (SHLCI-B) cases in Catalonia associated with mismatch from Influenza B virus strain included in the trivalent influenza vaccine (TIV). SHLCI-B was registered by the influenza sentinel surveillance system of Catalonia (PIDIRAC) during ten surveillance seasons from 2010 to 2020. Variables age, comorbidities, and vaccination status were recorded. Vaccine effectiveness was estimated as (1-OR) for intensive care unit (ICU) admission. Statistical significance was established at p < 0.05. A total of 1159 SHLCI-B were registered, of these 68.2% (791) corresponded to the 2017-2018 season; 21.8% (253) were admitted to ICU and 13.8% (160) were exitus; 62.5% (725) cases occurred in those aged >64 years; most frequent risk factor was cardiovascular disease (35.1%, 407) followed by chronic pulmonary obstructive disease-COPD (24.6%, 285) and diabetes (24.1%, 279). In four seasons, the predominant circulating lineage was B/Victoria, in two seasons the B/Yamagata lineage and four seasons had no IBV activity. Four seasons presented discordance with the strain included within the TIV. Vaccine effectiveness (VE) to prevent ICU admission was 31% (95% confidence interval [CI]: 4%-51%; p = 0.03); being 29% (95% CI: -3% to 51%) in discordant and 43% (95% CI:-43% to 77%) in concordant seasons. Significant differences were observed in the number of affected aged > 64 years (odds ratio [OR] = 2.5; 95% CI: 1.9-3.4; p < 0.001) and in patients with heart disease (OR = 2.40 95% CI: 1.7-3.4; p < 0.001), COPD (OR = 1.6 95% CI: 1.1-2.3; p = 0.01), and diabetes (OR = 1.5 95% CI: 1.1-2.1; p = 0.04) between discordant and concordant seasons. The increase in hospitalization rate in people> 64 years of age and those presenting comorbidities in seasons with circulating influenza B virus belonging to a lineage discordant with the strain included in the TIV and the decrease of VE to prevent ICU admissions evidence the vital need to administer the quadrivalent influenza vaccine regardless of the findings of predominant circulation in the previous season.
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4417-4424Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Maureen LA. Research in Personnel and Human Resources Management. Emerald Group Publishing Limited; 2007. https://www.emerald.com/insight/publication/doi/10.1016/S0742-7301(2007)26
Nielsen J, Vestergaard LS, Richter L, et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? Clin Microbiol Infect. 2019;25:1266-1276.
Ray R, Dos Santos G, Buck PO, et al. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccines Immunother. 2017;13:1640-1652. doi:10.1080/21645515.2017.1313375
Tafalla M, Buijssen M, Geets R, Vonk Noordegraaf-Schouten M. A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries. Hum Vaccin Immunother. 2016;12:993-1002. https://www.tandfonline.com/doi/full/10.1080/21645515.2015.1111494
Virk RK, Jayakumar J, Mendenhall IH, et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc Natl Acad Sci USA. 2020;117:619-628.
Caini S, Huang QS, Ciblak MA, et al. Epidemiological and virological characteristics of influenza B: results of the global Influenza B study. Influenza Other Respi Viruses. 2015;9:3-12.
Lei N, Wang HB, Zhang YS, et al. Molecular evolution of influenza B virus during 2011-2017 in Chaoyang, Beijing, suggesting the free influenza vaccine policy. Sci Rep 2019;9:2432. http://www.nature.com/articles/s41598-018-38105-1
Centers for Disease Control and Prevention. Tipos de virus de influenza | CDC. Accessed December 22, 2021. https://espanol.cdc.gov/flu/about/viruses/types.htm
Sharabi S, Drori Y, Micheli M, et al. Epidemiological and virological characterization of influenza B virus infections. PLoS One. 2016;11:e0161195. http://www.ncbi.nlm.nih.gov/pubmed/27533045
Horthongkham N, Athipanyasilp N, Pattama A, et al. Epidemiological, clinical and virological characteristics of influenza B virus from patients at the hospital tertiary care units in Bangkok during 2011-2014. PLoS One. 2016;11:e0158244. https://dx.plos.org/10.1371/journal.pone.0158244
Tran D, Vaudry W, Moore D, et al. Hospitalization for Influenza A Versus B. Pediatrics. 2016;138:e20154643. http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2015-4643
Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81-88. http://www.tandfonline.com/doi/abs/10.4161/hv.8.1.17623
Guozhong H, Yang P, Yan Q, Xiong C. Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines. Antimicrob Resist Infect Control. 2019:8.
Valesano AL, Fitzsimmons WJ, McCrone JT, et al. Influenza B viruses exhibit lower within-host diversity than influenza A viruses in human hosts. J Virol. 2020;94:94.
Martínez A, Soldevila N, Romero-Tamarit A, et al, Group and the S of HC of SI in CW. Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype. PLoS One. 2019;14:e0210353. http://dx.plos.org/10.1371/journal.pone.0210353
World Health Organization. Vaccine-preventable diseases surveillance standards. Influenza; 2018. Accessed December 29, 2021. http://www.who.int/influenza/resources/documents/influenza_
Suwannakarn K, Payungporn S, Chieochansin T, et al. Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assays. J Virol Methods. 2008;152:25-31.
Antón A, Marcos MA, Torner N, et al. Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain. Clin Microbiol Infect. 2016;22:564.e1-9. http://www.ncbi.nlm.nih.gov/pubmed/26939538
Mook P, Meerhoff T, Olsen SJ, et al. Alternating patterns of seasonal influenza activity in the WHO European Region following the 2009 pandemic, 2010-2018. Influenza Other Respi Viruses. 2020;14:150-161.
Puzelli S, Di Martino A, Facchini M, et al. Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017. BMC Infect Dis. 2019;19:990. doi:10.1186/s12879-019-4621-z
Ortiz de Lejarazu Raul, Domingo JD, Miguel ÁGDe, Torres FM, Quilo CG, Piedrafita B. Descripción de la gripe B en las epidemias estacionales de España. J Spanish Soc Chemother. 2018;31:511-519.
Eiros-Bouza JM, Perez-Rubio A. Impacto del virus gripal tipo B y divergencia con la cepa B incluida en la vacuna antigripal en España. Rev Esp Quim [Internet]. 2015;28:39-46. https://seq.es/wp-content/uploads/2015/02/seq_0214-3429_28_1_eiros.pdf
Basile L, Torner N, Martínez A, Mosquera MM, Marcos MA, Jane M. Seasonal influenza surveillance: observational study on the 2017-2018 season with predominant B influenza virus circulation. Vacunas. 2019;20:53-59. doi:10.1016/j.vacun.2019.09.003
Sharabi S, Drori Y, Micheli M, et al. Epidemiological and virological characterization of influenza B virus infections. PLoS One. 2016;11:e0161195. https://dx.plos.org/10.1371/journal.pone.0161195
Van Ranst M. Two B or not two B, that is the question. Statements in favor of the quadrivalent influenza vaccine. Vacunas. 2021;22:47-51. https://www.elsevier.es/es-revista-vacunas-72-articulo-two-b-or-not-two-S1576988720300388
European Centre for Disease Prevention and Control. Seasonal influenza, 2017-2018. ECDC Annual Epidemiology Report 2017; 2018. Accessed January 21, 2022. http://www.flunewseurope.org/archives
Caini S, Spreeuwenberg P, Kusznierz GF, et al. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014. BMC Infect Dis. 2018;18:269. http://www.ncbi.nlm.nih.gov/pubmed/29884140
Caini S, Kusznierz G, Garate VV, et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One. 2019;14:14.
Okoli GN, Racovitan F, Abdulwahid T, Righolt CH, Mahmud SM. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studies af. Vaccine. 2021;39:1225-1240. https://linkinghub.elsevier.com/retrieve/pii/S0264410X21000487
Martínez-Baz I, Navascués A, Pozo F, et al. Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. Hum Vaccines Immunother. 2015;11:1626-1633.
Soldevila N, Acosta L, Martínez A, et al. Behavior of hospitalized severe influenza cases according to the outcome variable in Catalonia, Spain, during the 2017-2018 season. Sci Rep 2021; 11:13587. www.nature.com/scientificreports
Godoy P, Romero A, Soldevila N, et al. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Eurosurveillance. 2018;23:1700732. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.43.1700732
Rajão DS, Pérez DR. Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture. Front Microbiol. 2018;9:123. http://journal.frontiersin.org/article/10.3389/fmicb.2018.00123/full